CAMBRIDGE, Mass., Jan. 24 /PRNewswire/ -- Peptimmune, Inc., a privately
held biopharmaceutical company announced today that it will be presenting at
the Piper Jaffray 17th Annual Health Care Conference on Wednesday, January 26,
2005 from 3:10 pm - 3:30 pm EST at The Pierre Hotel in New York. Peptimmune's
President and Chief Executive Officer, Thomas Mathers will be presenting an
overview of the company, and updates to the clinical development programs, GT
389-255 novel conjugate for the treatment of obesity and PI-0824 peptide
immunotherapy for the treatment of pemphigus vulgaris.
About Peptimmune Inc.
Peptimmune, Inc. is a privately held clinical stage biotechnology company
focused on utilizing both novel and proven technologies to improve the
therapeutic management of chronic autoimmune and metabolic disorders. The
company is developing second generation therapeutics that are expected to
result in safer and more effective products for obesity, multiple sclerosis,
rheumatoid arthritis and pemphigus vulgaris. Founded by a team of world class
scientists and led by an experienced management team, Peptimmune's mission is
to reduce the burden these diseases place on the individuals, their families
and the healthcare system. For additional information, visit the company's
website at http://www.peptimmune.com .
SOURCE Peptimmune, Inc.
 back to top
Related links:
http://www.peptimmune.com
CONTACT:
Thomas P. Mathers, +1-617-715-8040, President
and Chief Executive Officer, or tom.mathers@peptimmune.com, of
Peptimmune, Inc.
|
